Bank of Montreal
MGX icon

Bank of Montreal’s Metagenomi Therapeutics MGX Stock Holding History

Bank of Montreal’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,441
Closed -$18.3K – 3789
2025
Q1 		$18.3K Hold
13,441
– – ﹤0.01% 3234
2024
Q4 		$48.5K Buy
13,441
+1,000
+8% +$2.41K ﹤0.01% 3117
2024
Q3 		$25.4K Buy
+12,441
New +$43.2K ﹤0.01% 3541

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Montreal's MGX Position: Q2 2025 in Review

Bank of Montreal sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 13,441 shares — an estimated $18.3K sold.

Bank of Montreal first reported a position in MGX in Q3 2024 and held it in 3 quarters. The position peaked at $48.5K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Bank of Montreal reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bank of Montreal sold 13,441 Metagenomi Therapeutics shares in Q2 2025, an estimated $18.3K.
  • Bank of Montreal first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 3 quarters.
  • Bank of Montreal's Metagenomi Therapeutics position peaked at $48.5K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Bank of Montreal's 13F filing for Q2 2025, filed 5 Aug 2025.